• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Maxygen, Inc. (Maxygen) is a biotechnology company focused on the development of its MAXY-G34 product candidate. MAXY-G34 is a pegylated, granulocyte colony stimulating factor (G-CSF), for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome (ARS). On May 16, 2011, Astellas Pharma Inc. (Astellas) acquired the Companys interests in Perseid Therapeutics LLC, the Companys former subsidiary, which included all of the Companys research and development operations. As a result of the transaction, the Company has reclassified the operating results of Perseid, as well as any related business activities, to discontinued operations. The Companys wholly owned subsidiaries include Maxygen Holdings (U.S.), Inc., Maxygen ApS and Maxygen Holdings, Inc., and its majority owned subsidiary, Maxygen Holdings LLC.
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
BORKHOLDER JOHN GENERAL COUNSEL & SECRETARY |
|
80,684 | 2013-08-13 | 0 |
|
SULAT JAMES R FORMER CEO & CFO |
|
No longer subject to file | 2013-06-30 | 0 |
|
357,562 | 2012-06-06 | 0 | |
|
62,964 | 2012-06-06 | 0 | |
|
64,000 | 2012-06-06 | 0 | |
|
60,000 | 2012-06-06 | 0 | |
|
635,904 | 2011-05-19 | 0 | |
|
YONEHIRO GRANT SENIOR VICE PRESIDENT |
|
No longer subject to file | 2011-05-16 | 0 |
|
No longer subject to file | 2010-03-18 | 0 | |
|
No longer subject to file | 2009-12-30 | 0 | |
|
GOLDSTEIN ELLIOT CHIEF OPERATING OFFICER |
|
No longer subject to file | 2009-10-30 | 0 |
|
BRISCOE LAWRENCE W SENIOR VICE PRESIDENT AND CFO |
|
No longer subject to file | 2009-09-30 | 0 |
|
HOWARD RUSSELL J CHIEF EXECUTIVE OFFICER |
|
No longer subject to file | 2009-09-30 | 0 |
|
VETTICADEN SANTOSH CHIEF MEDICAL OFFICER |
|
0 | 2008-07-01 | 0 |
|
GREENWOOD MRC |
|
0 | 2008-05-30 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
